Revenue $2.91 billion $2.78 billion $2.52 billion 15.7% Net Income (non-GAAP) $1.04 billion N/A $1.10 billion (5.5%) R&D and SG&A expenses (non-GAAP) $1.21 billion N/A $984 million 22.9% Vertex ...

What do you wonder? By The Learning Network A new collection of graphs, maps and charts organized by topic and type from our “What’s Going On in This Graph?” feature. By The Learning ...

(Image: Pixabay) HDFC Bank, ICICI Bank and Axis Bank, the top three private sector banks in India, have declared their earnings for the third quarter of FY25. ICICI Bank was the last to announce ...

Symmetry is when one side of a shape is a mirror image of the other side. Lots of buildings and everyday objects use symmetry because it looks appealing to the human eye. Watch the video below ...

CNBC's Becky Quick reports on the latest news. Russia and US to meet for talks on Ukraine’s future after sidelined European leaders gather for emergency summit 'Always Sunny' Star Offers to Pay ...

Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal ...

Here's why they think Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX) could trounce the market in 2025. David Jagielski (Eli Lilly): For years ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The administrator will mark the sounds you hear on an audiogram. The Y-axis (vertical) measures the intensity, or loudness, of the sound. It’s measured in decibels (dB) and ranges from -10 to ...

The Board of Directors of Symmetry Group Limited (PSX: SYM) has allowed the company to explore capital-raising options, including an initial public offering (IPO) for new product companies such as ...

“2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch ...